Diazyme's HDL-Cholesterol Assay is a direct dual liquid stable reagent system. Convenient instrument specific packaging options including Roche™ Hitachi 917 series, Beckman AU (400/600/640/680), Beckman Synchron CX, LX and DXC. The assay utilizes Diazyme's proprietary PVSPEGME coupled technology which provides outstanding performance.
| Product | Catalog Number | Format | Method |
|---|---|---|---|
| Kit | DZ129A | R1/R2 (Dual Vial Liquid Stable) | Dual Vial Liquid Stable, PVSPEGME Coupled |
| Calibrator | DZ130A-CAL | Cal: 1 Level (Lyophilized) | |
| Control | DZ248A-CON | Con: 3 Level (Lyophilized) |
Product Features
Diazyme's HDL-Cholesterol Assay is a direct dual liquid stable reagent system. Convenient instrument specific packaging options including Roche™ Hitachi 917 series, Beckman AU (400/600/640/680), Beckman Synchron CX, LX and DXC. The assay utilizes Diazyme's proprietary PVSPEGME coupled technology which provides outstanding performance. The assay features a linear range of 1.06 to 184.8 mg/dL, intra and inter %CV values < 5 % and less than 10% interference from triglycerides to 1000 mg/dL, ascorbic acid to10 mmol/L, bilirubin to 40 mg/dL, bilirubin conjugate to 30 mg/dL, hemoglobin to 1000 mg/dL.
Downloads
Assay Principle
The assay is based on a modified polyvinyl sulfonic acid (PVS) and polyethylene-glycol-methyl ether (PEGME) coupled classic precipitation method with the improvements in using optimized quantities of PVS/PEGME and selected detergents. LDL, VLDL and chylomicron (CM) react with PVS and PEGME and the reaction results in inaccessibility of LDL, VLDL and CM by cholesterol oxidase (CHOD) and cholesterol esterase (CHER). The enzymes selectivity react with HDL to produce H2O2 which is detected through a Trinder reaction.
Intended use
The Diazyme HDL-Cholesterol reagent is intended for the in vitro quantitative determination of High Density Lipoprotein Cholesterol in human serum or plasma. The reagent can assist in the diagnosis and treatment of patients at risk for developing coronary heart disease.
Regulatory Status
